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Accurate inguinal and pelvic nodal staging in anal cancer is important for the prognosis and planning of radiation fields. There is
evidence for the role of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in the staging and management of cancer,
with early reports of an increasing role in outcome prognostication in a number of tumours. We aimed to determine the effect of
FDG-PET on the nodal staging, radiotherapy planning and prognostication of patients with primary anal cancer. Sixty-one consecutive
patients with anal cancer who were referred to a tertiary centre between August 1997 and November 2005 were staged with
conventional imaging (CIm) (including computed tomography (CT), magnetic resonance imaging, endoscopic ultrasound and chest
X-ray) and by FDG-PET. The stage determined by CIm and the proposed management plan were prospectively recorded and
changes in stage and management as a result of FDG-PET assessed. Patients were treated with a uniform radiotherapy technique and
dose. The accuracy of changes and prognostication of FDG-PET were validated by subsequent clinical follow-up. Kaplan–Meier
survival analysis was used to estimate survival for the whole cohort and by FDG-PET and CIm stage. The tumour-stage group was
changed in 23% (14 out of 61) as a result of FDG-PET (15% up-staged, 8% down-staged). Fourteen percent of T1 patients (3 out of
22), 42% of T2 patients (10 out of 24) and 40% of T3–4 patients (6 out of 15) assessed using CIm, had a change in their nodal or
metastatic stage following FDG-PET. Sensitivity for nodal regional disease by FDG-PET and CIm was 89% and 62%, respectively. The
staging FDG-PET scan altered management intent in 3% (2 out of 61) and radiotherapy fields in 13% (8 out of 61). The estimated
5-year overall survival (OS) and progression-free survival (PFS) for the cohort were 77.3% (95% confidence interval (CI):
55.3–90.4%) and 72.2% (95% CI: 51.5–86.4%), respectively. The estimated 5-year PFS for FDG-PET and CIm staged N2-3 disease
was 70% (95% CI: 42.8–87.9%) and 55.3% (95% CI: 23.3–83.4%), respectively. FDG-PET shows increased sensitivity over CIm for
staging nodal disease in anal cancer and changes treatment intent or radiotherapy prescription in a significant proportion of patients.
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Anal cancer is rare with an incidence around 2 in 100000 per year.
The treatment of this tumour has changed dramatically over the
last 25 years (Ryan et al, 2000). Since the report on combined pre-
operative chemo-radiotherapy (CRT) for squamous cell carcinoma
(SCC) of the anus by Nigro et al (1974), a number of multi-centre
randomised trials have confirmed its benefit (Flam et al, 1996;
Bartelink et al, 1997). Complete tumour regression occurs in 68–
100% of tumours, resulting in a high rate of sphincter preservation
(Sato et al, 2005). Chemo-radiotherapy has thus become the
standard of care, with surgery reserved for salvage treatment
following local failure.
Accurate clinical staging in anal cancer is essential both for
prognostic information and for planning of radiotherapy fields and
technique. Tumour size, depth of invasion and presence of nodal
metastases are key predictors of both overall and disease-free
survival (Klas et al, 1999). Although nodal stage is related to
tumour size, it also has an independent prognostic value (Frost
et al, 1984). The accurate identification of disease extent permits
precision radiotherapy delivery, ensuring the accurate coverage of
disease and sparing of organs at risk.
Current standards in staging anal cancer include physical
examination to determine the primary stage, with biopsy of the
primary tumour and fine needle aspiration (FNA) of clinically
suspicious inguinal nodes. Computed tomography (CT) is the
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smost commonly used conventional cross-sectional imaging
method to stage lymph nodes and distant metastases in the pelvis
and abdomen. However, the sensitivity of CT for regional lymph
nodes in anal cancer and other pelvic malignancies is approxi-
mately 50% (Weinerman et al, 1983; Matsukuma et al, 1989; Sato
et al, 2005).
Positron emission tomography (PET) has a rapidly expanding
role in oncology, with evidence for its role in the staging and
management of a number of tumour types. The fact that PET
imaging is functional rather than structural limits its value in local
tumour staging, but numerous studies have shown an effect in the
identification of regional and distant disease (Rinne et al, 1998;
Dwamena et al, 1999; Gould et al, 2001; Hellwig et al, 2001; Kalff
et al, 2002), treatment decisions (MacManus et al, 2001; Spaepen
et al, 2001; Blum et al, 2003; Heriot et al, 2004), radiotherapy
planning (Haustermans et al, 2002; MacManus and Hicks, 2003;
Leong et al, 2006) and in the prediction of response (Di Fabio et al,
2005; Duong et al, 2006).
A role for 18-fluorodeoxyglucose positron emission tomography
(FDG-PET) as a useful imaging modality for anal cancer given the
limitations of CIm has been suggested. In this paper, we aim to
determine the effect of FDG-PET on the nodal staging, radio-
therapy planning and prognostication of patients with primary
anal cancer.
MATERIALS AND METHODS
Patient population
Sixty-one consecutive staging PET scans acquired on patients
referred to the Gastrointestinal Unit at the Peter MacCallum
Cancer Centre (PMCC) with primary anal cancer between August
1997 and November 2005 form the basis for this study. The scans
were obtained as part of routine clinical practice and identified
from a prospective PET database. Eligibility criteria required PET
scans to be performed before definitive treatment and within 30
days of conventional staging investigations. Referring clinicians
prospectively completed a management decision proforma before
PET stating their proposed management plan for the patient in the
light of the current clinical and imaging information available.
Referring physicians who had not completed a management plan
were contacted and asked to provide a plan before performing the
PET scan on that particular patient.
All patients had histologically proven localised primary SCC of
anal canal or verge, were prepared to receive radical radiotherapy
and had signed informed consent for entry into the PET centre
database.
The collection of impact data and outcome was approved by the
institutional ethics committee.
Determination of stage
The disease was staged according to the 6th American Joint
Commission on Cancer staging system (2002).
All 61 patients underwent assessment with history, physical
examination and biopsy of the primary. Primary tumour size was
determined by digital rectal examination (and/or examination
under anaesthesia). Eight patients had endorectal ultrasound in
addition to local staging. Sixteen patients with T1 tumours
underwent excisional biopsy of the primary before PET.
Conventional imaging (CIm) for regional and distant metastasis
included imaging of the pelvis, abdomen and chest. Fifty-nine
(97%) patients underwent cross-sectional imaging of the pelvis (41
CT alone, 17 CT and magnetic resonance imaging (MRI), and 1
MRI alone). The two patients in whom no pelvic imaging was
performed both had T1 tumours and were stage 1 on PET. Owing
to the prevalence of reactive lymphadenopathy in the inguinal
region, we considered lymph nodes up to 15mm to be within
normal limits on CT criteria. The inguinal nodes considered as
involved on clinical examination were confirmed either with fine
needle aspiration cytology (FNAC) or with excisional biopsy.
Sixty-three percent of the inguinal nodes reported as involved on
CT were confirmed histologically.
Fifty-eight (95%) patients underwent a CT of the abdomen and
46 (75%) underwent chest imaging (35 CT, 11 CXR) to stage for
distant disease. Computed Tomography staging for distant disease
is now considered standard of care; this was not the case in the
initial study period. However, given the very low incidence of
metastatic disease at presentation in anal cancer, this is unlikely to
influence the results. The three patients who did not have CIm for
distant disease in the abdomen were staged as N0.
All 61 patients underwent a staging PET scan, of whom 36 had
PET and 25 had PET CT.
FDG-PET imaging and interpretation
All patients fasted for 6h before this study but were encouraged to
drink water. Patients were catheterised when possible and were
given 10–20mg furosemide 30min before imaging to minimise the
confounding effects of changing bladder activity on pelvic
assessment. Patients also received bowel preparation before the
procedure.
PET scans were acquired on a GE QUEST 300-H scanner (UGM
Medical Systems, Inc., Philadelphia, PA, USA) and PET CT scans
on a dedicated PET-CT scanner (Discovery; GE Healthcare,
Chalfont, St Giles, UK) at least 1h after intravenous injection of
300–400MBq of 18F-FDG. The measured resolutions of PET and
PET-CT were comparable, and although attenuation correction
and anatomical correlation on PET-CT provide greater confidence
in the detection and localisation of disease, the data are reasonable
to combine as technology continues to improve and this represents
a likely worst case scenario with respect to the benefits of PET/CT
over conventional evaluation.
Transmission and emission scans were obtained from the lower
neck to the upper thigh. Patients were scanned with their arms
raised, if they could tolerate it. Emission data were processed using
iterative reconstruction (Fulham et al, 1997) (ordered-subset
expectation maximisation method) with attenuation correction
(Benard et al, 1999). Robust co-registration of non-contempora-
neous PET and CT data used rigid, mutual information matching.
As the pelvic lymph nodes are relatively immobile and in a
relatively fixed geometry in reference to bone anatomy, we believe
that this approach is valid.
Image datasets were reported from the screen, both with and
without attenuation correction, using an interactive display
programme that allows multiple orthogonal images to be shown
simultaneously. Rotating count-rendered images were also
reviewed to aid clarification of the relationship between the
physiological radiotracer accumulation and tumour in the rectum.
All PET and PET-CT studies were reported at the time of the
scan by experienced PET specialists. The PET stage was
determined by incorporating the PET or PET-CT findings with
all other staging information available at the time of clinical
reporting. This was abstracted from the clinical report issued
thereafter. As per usual clinical practice, the scans were read
blinded to the results of subsequent tests and the final outcome of
the patient. Significant structural imaging abnormalities did not
influence the PET or PET-CT result if there was no associated FDG
PET or PET-CT metabolic abnormality. For chest, abdominal or
pelvic activity, the focal uptake of 18F-FDG had to be greater than
the mediastinal uptake, and needed to correspond to an
anatomical structure or abnormality identified on CT; for example,
a lymph node of normal or abnormal size. An activity less than the
mediastinal activity was defined as abnormal only if there was a
definite structural abnormality of o1cm in size. This assessment
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sis justified because of the known partial volume effect of PET-CT
caused by its limited resolution below 1cm.
Assessment of PET impact
The PET request form incorporated a management decision
proforma that required the referring physician to state tumour
histology, results of structural imaging investigations, and the
TNM and group stage thereby obtained, as well as the proposed
management plan and intent based on CIm if PET were
unavailable. The post-PET plan and intent were determined from
the medical record or through direct contact with the referring
clinician. The PET scan result was subsequently compared with the
CIm result by stage group, nodal stage and the actual management
implemented. Changes in the radiation field or technique were
assessed from a review of the radiotherapy treatment sheets and
planning data.
The effect on management was considered high when the
treatment intent was changed from palliative to curative or visa
versa, medium when the method of treatment delivery was
changed, such as a change in radiation field size or technique,
and low when the PET results did not indicate a need for
management change. PET was considered to have had no effect
when the management plan was not changed despite being
inconsistent with the post-PET stage. This system of assessing
PET impact by our institution has been validated and published
for other tumours, including lung cancers (MacManus et al, 2001),
non-Hodgkin’s lymphomas (Blum et al, 2003) and oesophageal
cancers(Duong et al, 2006).
Chemo-radiation
All patients appropriate for radical treatment were managed with
definitive radiation combined with 5-FU and mitomycin-C
according to the hospital protocol or within trial. Radiation was
delivered by an external beam using 6 or 18MV photons to a total
dose of 54 Gray (Gy) in 1.8Gy daily fractions, five fractions per
week using a three-phase technique. Phase 1 consisted of anterior/
posterior parallel opposed fields, with the clinical target volume
(CTV) including the primary tumour, perirectal, inguinal and iliac
lymph nodes to a dose of 36Gy, and with the upper field border
4cm superior to gross disease (primary or nodal). Phase 2 used a
three-field technique to the posterior pelvis with the same upper
field borders, with CTV encompassing the gross disease, perirectal
and iliac nodes to a dose of 45Gy. Phase 3 treated the primary
disease to a total dose of 54Gy, using a reduced field size (2cm on
gross disease). The involved inguinal nodes were boosted to 54Gy
using electron fields. Patients with only stage 1 disease received the
same total doses to primary tumour, perirectal and iliac nodes
using a two-phase posterior pelvis technique.
Data from PET were used to assist in radiotherapy treatment
planning, but image co-registration was not used. The standard
concurrent chemotherapy was 5-FU 1gm
–2 for 4 days in week 1
and 5, and mitomycin C 10mgm
–2intravenously on the first day
of treatment only. Some patients received concurrent chemo-
therapy within a clinical trial using continuous infusion 5-FU
300mgm
–2 for 96h every week throughout the course of
radiotherapy, and mitomycin C 10mgm
–2 intravenously on the
first day of treatment only.
Follow-up and validation of results
Patients were followed up by review of their case notes and
through contact with their referring physician to determine clinical
outcomes. When appropriate, details of the date and cause of death
were obtained. The site and date of any progression were recorded.
Confirmation of the presence, absence or equivocal status of
disease at each site was determined by predefined protocol criteria
for both CIm and PET. Methods of validation of accuracy were
defined in the protocol and included pathology, therapeutic
response, imaging, clinical follow-up and concordance between
CIm and PET. Concordance was used if CIm and PET were
negative at a nodal site within the radiation treatment field. Sites
were considered not assessable by CIm if not imaged as part of
follow-up (with the exception of the primary and inguinal nodes
that were considered assessable by clinical examination).
Statistical methods
The proportion of patients having a change in stage group after the
staging PET scan was calculated together with the 95% confidence
interval (CI), calculated using the exact methods for binomial
distribution.
Overall survival (OS) was measured from the date of the staging
PET scan to the date of death from any cause. Progression-free
survival (PFS) was measured from the date of the staging PET scan
to the date of first progression at any site or death from any cause.
All patients were followed up to a study close-out (study censor)
date of 17 August 2006. The survival times of those patients not
experiencing the relevant event (death and/or progression) by the
close-out date were censored on that date.
The Kaplan–Meier product limit method was used to estimate
OS and PFS, and 95% CI for the proportion of patients surviving at
particular times was estimated using the logit transformation. The
Mantel–Cox log-rank test was used to compare PFS according to
stage group and nodal stage assessed using CIm and PET. The
reverse Kaplan–Meier method was used to estimate the potential
follow-up time. All statistical analyses were conducted using
StatXact (Cambridge, MA, USA: Cytel Software Corporation; 2003)
and S-Plus (Seattle, WA, USA: Mathsoft; 1999) statistical software.
RESULTS
The median age of the 61 patients with primary anal cancer who
underwent
18F-FDG PET was 57 years (range 27–88 years), and
56% (34) were female and 44% (27) were male.
Staging
Excisional biopsy had been carried out before PET in 16 patients.
The primary tumour was identified by PET in 100% of the
remaining cases (45 out of 45). However, as discussed earlier, PET
was not used to formally determine the T stage. Stage by CIm and
with the addition of PET are recorded in Table 1. Stage group was
changed by PET in 23% (14 out of 61) of patients (95% CI: 13–
35%). Fifteen (9 out of 61) percent of patients were up-staged and
8% (5 out of 61) of patients were down-staged. In 77% (47 out of
61), the stage group was unchanged (Table 2).
Changes in the nodal stage were greater for tumours with a more
advanced T stage. Only 14% (3 out of 22) of patients with T1
tumours had a change in nodal stage after PET, whereas 42% (10
out of 24) and 38% (6 out of 16) of patients with T2 and T3/4
tumours, respectively, had a change in nodal (regional or
metastatic) stage after PET.
The accuracy of the post-PET nodal stage could be validated in
the majority of cases (98, 94, 90 and 89% for intra-abdominal,
inguinal, perirectal and iliac sites of disease, respectively). PET
results of the regional nodal sites not validated were not assessable
because of discordance with CIm results (or, in two cases, no CIm
of the pelvis) at sites encompassed by radiation fields. In only one
case was the PET intra-abdominal nodal result unable to be
validated as a true negative, as the patient died within 12 months of
follow-up of unrelated causes. In all cases where PET and CIm
staging for metastatic disease differed, PET was subsequently
validated as correct.
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superior sensitivity for staging in anal cancer. The overall
sensitivity for detection of regional nodal metastases was 89 vs
62% for PET vs CIm. Sensitivity for PET vs CIm for the detection of
perirectal, inguinal, iliac and intra-abdominal nodes was 67 vs
50%, 100 vs 85%, 100 vs 50% and 100 vs 0%, respectively. In four
patients intra-abdominal CIm staging could not be validated, three
had no conventional abdominal imaging as part of staging and one
died within 12 months of follow-up. Twenty-five percent (15 out of
61) of patients did not have chest imaging as part of staging and,
therefore, this was not included in the analysis of accuracy.
Management
Ninety-seven percent (59 out of 61) of patients were treated with
radical intent, of which 97% (57 out of 59) received definitive CRT.
One patient with stage 1 disease was treated with excision biopsy
alone (patient decision) and one patient with systemic lupus
received a lower neoadjuvant dose of CRT followed by definitive
surgery. Of the 3% (2 out of 61) of patients treated with palliative
intent, one patient with advanced loco-regional disease received
palliative dose RT alone because of medical co-morbidity and one
patient with metastatic nodal disease received high-dose palliative
CRT.
PET changed management in 16% (10 out of 61) of cases. The
addition of PET to CIm staging had a high impact, changing
treatment intent in 3% (2 out of 61) of patients. PET staging had a
medium impact, changing radiotherapy fields or technique to
cover or exclude nodal disease in 13% (8 out of 61) of patients
(Figures 1 and 2). The results of PET were ignored (that is, no
impact) in management in 8% (5 out of 61) of patients. In these
patients, PET stage changes would potentially have altered
management intent or treatment fields, but were ignored. Table 3
shows PET changes in nodal stage by T stage, the effect on
management and details of the resulting changes in radiation
fields. For the remaining 77% (47 out of 61) of patients, PET did
not affect on the earlier planned management because the PET
results were concordant with those of CIm.
Prognostication
The median potential follow-up from the date of the PET scan to
the close-out date was 2.6 years (95% CI: 2.1–3.1 years). All 61
patients were included in the survival analysis. By the close-out
date of 17 August 2006, eight had died and a further four had
progressed with disease.
Estimated 5-year OS and PFS were 77.3% (95% confidence
interval : 55.3–90.4%) and 72.2% (95% CI: 51.5–86.4%),
respectively (Figures 3 and 4).
Progression-free survival was analysed by nodal stage, as staged
by CIm (Figure 5) and PET (Figure 6). Owing to small numbers,
the nodal stage was grouped as N0–N1 and N2–N3. Of the 61
patients, 42 were CIm N stage 0–1 (five progressed or died) and 19
were CIm N stage 2–3 (seven progressed or died). The 3-year PFS
rate was 89.8% (95% CI 75.7–96.1%) for N stage 0–1 and 73.7%
(95% CI 50.2–88.6%) for N stage 2–3.
Of the 61 patients, 41 were PET N stage 0–1 (six progressed or
died) and 20 were PET N stage 2–3 (six progressed or died). The 3-
year PFS rate was 87.1% (95% CI 72.3–94.5%) for N stage 0–1 and
80.0% (95% CI 57.2–92.3%) for N stage 2–3 (Figure 6).
In patients with N2–3 disease, the estimated 5–year PFS for
FDG-PET and CIm was 70% (95% CI: 42.8–87.9%) and 55.3%
(95% CI: 23.3–83.4%), respectively.
DISCUSSION
As shown with other tumour types (Dwamena et al, 1999; Gould
et al, 2001; Hellwig et al, 2001; MacManus et al, 2001), this study
too showed that the addition of PET to the staging of patients with
SCC of the anus changes stage in a substantial proportion. Overall,
23% of cases had a change in stage group and 40% of patients with
T2 or larger tumours had a change in nodal stage as a result of
PET. The accuracy of these nodal stage changes by PET could be
validated in 93% of patients.
There is currently limited published data regarding the clinical
impact of PET in addition to conventional staging for anal cancer.
Trautmann et al reported 21 patients with anal cancer, a quarter of
whom were found to have involved pelvic nodes on PET not seen
on CT, although the group stage was changed only in about 10%.
The lower rate of stage change in this study may well have been
because of the lack of attenuation correction of PET scans, which
would limit sensitivity in detecting deep pelvic lymph node
disease. Cotter et al (2006), reported 41 patients staged with CT
and FDG-PET/CT and found PET-upstaged inguinal nodes in 17%
of cases in which both CT and physical examination were negative.
In our cohort of 61 patients, the addition of PET showed superior
sensitivity for regional node staging compared with CIm alone (89
vs 62%, respectively). The sensitivity of PET vs CIm for inguinal
node metastasis was 100 vs 85, with 63% of patients having
histological confirmation.
The limitations of PET in identifying peri-rectal nodal disease
(N1) are recognised. In our cohort, the sensitivity of PET for peri-
rectal nodes was 67%. The spatial resolution of PET (10mm) and
the spillover of activity from the primary tumour limit the
detection of these lymph nodes adjacent to the primary. The true
accuracy of peri-rectal node detection by PET may not be relevant,
Table 2 Comparison of stage group for the 61 patients by CIm vs PET
Number of patients by
stage group using CIm
I II IIIA IIIB IV
Number of patients by
stage group using PET
I1 8 0 01 0
II 0 13 2 1 0
IIIA 0 1 3 0 1
IIIB 2 3 1 13 0
IV 0 0 0 2 0
Abbreviations: CIm¼conventional imaging; PET¼positron emission tomography.
Table 1 Stage group and TNM stage by CIm and PET
Stage
group
TNM
stage
CIm Stage PET Stage
Stage group TNM Stage group TNM
No. (%) No. (%) No. (%) No. (%)
I T1N0M0 20 (33) 20 (33) 19 (31) 19 (31)
II T2N0M0 17 (28) 14 (23) 16 (26) 14 (23)
T3N0M0 3 (5) 2 (3)
IIIA T1N1M0 6 (10) 0 (0) 5 (8) 0 (0)
T2N1M0 2 (3) 1 (2)
T3N1M0
T4N0M0 0 (0) 1 (2)
4 (7) 3 (5)
IIIB T4N1M0 17 (28) 1 (2) 19 (31) 1 (2)
AnyTN2M0 7 (11) 12 (20)
AnyTN3M0 9 (15) 6 (10)
IV
a AnyTAnyNM1 1 (2) 1 (2) 2 (3) 2 (3)
Total 61 61 61 61
Abbreviations: CIm¼conventional imaging; PET¼positron emission tomography;
RT¼Radiotherapy; TNM¼Tumour, Nodes, Metastases.
aM1 disease identified was
distant nodal metastases. No visceral metastases were identified.
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the high-dose radiation treatment volume.
It is well recognised that the risk of nodal involvement increases
in tumours with size 42cm (X stage T2). In tumours with size
42cm, nodal involvement rose to 45–50%, justifying the common
practice of prophylactic inguinal and iliac nodal irradiation in
these patients. Some recent literature reports excellent disease
control for involved field RT without prophylactic nodal irradia-
tion in T1 tumours in 21 patients (Hatfield et al, 2008) or suggests
reducing the target volume to the anal canal and/or the lower
perirectal nodes (Ortholan et al, 2005). However, we found that
even in T1 tumours of the anal canal there was a 10–15% risk of
nodal involvement, which is not clinically insignificant and may
caution against treatment to the primary alone in these patients. In
contrast, none of the T1 tumours of the anal verge had nodal
involvement on either CIm or PET.
Without surgical nodal staging, it is not possible to determine
the specificity of PET (true negative rate). As all nodal areas were
treated prophylactically, follow-up and imaging could not be used
as surrogates and all discordant results could not be verified by
biopsy, no attempt was made to estimate the specificity. However,
studies in other pelvic malignancies have shown PET to be highly
specific for nodal spread, with specificities of 95% for inguinal
nodes in vulval cancer (Cohn et al, 2002) and over 90% for pelvic
nodes in cervical cancer (Reinhardt et al, 2001). Low FDG uptake
in inguinal nodes is sufficient, in our experience, to exclude
malignancy, but if critical to patient treatment decisions, excisional
biopsy should be carried out. The poor outcome of the two
PET positive node
Primary
Ph 1 Clm field Ph 2 Clm field Ph 3 Clm field
Ph 1 PET sup border Ph 2 PET sup border Ph 3 PET sup border
Figure 1 Radiograph with schematic representation of primary and PET-detected node and showing three-phase pelvic RT fields for stage by CIm
(T3N0M0) and change in superior borders by PET stage (T3N2M0).
Pelvic node Primary
Figure 2 PET scan showing primary; the left iliac node metastasis was not identified on CIm and changed RT fields.
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weight to the positive predictive value of PET and is consistent
with a recent study in which the specificity of PET for para-aortic
nodes was again shown to be 95% (Rose et al, 1999), as well as
highlights its strength as a whole-body screening modality in
excluding or detecting systemic metastases.
PET is relatively insensitive for involved nodes with size
o8mm, because of partial volume effects; however, these are also
below the size limits for a positive node on both CT and MRI.
Thus, false-negative results on PET are also false negative or at best
equivocal on CT and MRI. The real advantage of PET lies in the
high positive predictive value of significantly increased uptake in
non-enlarged nodes.
Although new MRI sequences and the use of lymphatic contrast
agents (for example, USPIO) may increase the sensitivity for nodal
disease, these remain under investigation and have not yet entered
routine clinical practice. However, they may well provide com-
plementary anatomical staging information to PET in the future.
Table 3 PET changes in nodal stage by T stage and impact of changes on management
CIm nodal stage PET nodal stage Impact RT field changes due to PET
Primary tumour stage
T1
N0 N3 (ili) None Radiation fields planned as for stage 1 disease. (i.e. 2 phase posterior
pelvis with no prophylactic inguinal node RT)
N0 N2 (R ili) None
N3 (bil ili) N0 Medium Phase 3 boost to primary only
T2
N0 N2 (ili) None Phase 1 and 2 fields upper border not changed. Phase 3 boost to primary only
N3 (ing+ili) N3M1 (PAN) None Patient treated with radical intent (PAN not treated). Subsequently progressed in PAN
N1 N0 None Peri-rectal nodes remote from primary. No phase 3 boost field size reduction from phase 2
N0 N1 Low Proximity of peri-rectal nodes to primary meant included in phase 3 boost to
primary without requiring change in field size
N1 N0 Low
N2 (R ing) N3 (ing+p-r) Low
N3 (ing+p-r) N2 (R ing) Low
N0 N3 (R ili+p-r) Medium Superior border increased phase 1 and 2 fields. R ili node covered in phase 3 boost
N2 (R ing) N0 Medium No phase 1 field change or phase 2/3 electron boost to R groin
N3 (bil ing) N2 (R ing) Medium No phase 1 field change or phase 2/3 electron boost to L groin
T3/4
N0
a N2 (L ili) Medium Superior border phase 1 and 2 fields increased to cover iliac nodes. L ili covered in phase 3 boost
N3 (bil ing) N2 (R ing) Medium No phase 1 field change or phase 2/3 electron boost to L groin
N0 N2 (L ing) Medium Phase 1 field change and phase 2/3 electron boost L groin
N3 (L ing p-r) N3 (bil ing/ili) Medium Phase 1 and 2 field changes. Phase 2/3 electron boost to bilateral groins
N3M1 (ing +PAN) N1M0 High Intent changed from palliative to radical
N3M0 (p-r,ing +ili) N3M1 (PAN) High Intent and dose changed from radical to palliative
Abbreviations: bil, bilateral; CIm¼conventional imaging; Ili, iliac; ing, inguinal; L¼left; PET¼positron emission tomography; p-r, peri-rectal; PAN, para-aortic nodes; R¼right;
RT¼Radiotherapy; TNM¼Tumour, Nodes, Metastases.
aChanges to radiotherapy fields and PET scan for this patient are shown in Figures 1 and 2.
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Figure 4 Kaplan–Meier curves of progression-free survival for all
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(SLNB) to determine those patients in whom prophylactic inguinal
node irradiation can be safely omitted has been raised. A recent
review of five studies of SLNB in anal cancer (Damin et al, 2006)
concluded this technique as safe, effective and potentially
important in guiding management. These studies are limited by
their small numbers and their inability to determine the sensitivity
of the technique. However, in contrast to breast cancer and
melanoma, for which SLNB is now standard of care, surgical
management of involved nodes is not standard in anal cancer, and
the difficulty in obtaining adequate experience to validate results
may ultimately limit its usefulness in this disease.
Treatment intent was only changed in 3% of patients, as anal
cancer is predominantly a locoregional disease at presentation.
However, radiation fields were altered as a result of PET in 13%.
For the larger T3/4 tumours, management was changed in 100% of
cases in which PET altered nodal stage. The reliance on follow-up
and survival data to validate PET findings and appropriateness of
management changes has limitations. Retrospective assessment of
outcomes can be flawed and a long timescale between diagnostic
tests and clinical outcomes makes this more difficult. Despite this,
our findings still strongly suggest that management changes
influenced by PET findings were usually appropriate.
The benefit from modifying radiation treatment volumes to
incorporate areas found to be abnormal by PET, but not by CT,
cannot be independently assessed by this study. However,
intuitively, failure to treat active sites of disease ought to be
detrimental. In terms of allowing individualisation of treatment,
PET is an attractive adjunct.
The dose of radiation concurrent with chemotherapy required to
treat anal cancer is open to debate. Using our centre’s technique,
inguinal nodes were routinely treated to at least 36Gy and lower
iliac nodes treated to 45Gy prophylactically for all but the lowest
risk patients (stage I). All known gross diseases were treated to
54Gy. This approach seems to be justified by the excellent results
from our cohort, however, lower doses may be adequate to reduce
the risk of toxicity. There is evidence to suggest that doses as low
as 30Gy in combination with chemotherapy are sufficient for
microscopic diseases (Hu et al, 1999), and that some anal cancer
techniques, such as that used in the UK ACT II study, treat nodal
areas only 30.6Gy prophylactically. A recent publication suggests
that these doses may even be sufficient to treat non-bulky primary
disease (Hatfield et al, 2008). The effect of PET changes in
treatment fields and the influence of these on outcome are,
therefore, potentially greater in centres where prophylactic doses
to nodal areas are lower because of differing doses and techniques.
Nodal stage as assessed by CIm was significantly associated with
PFS in our cohort. However, PFS using PET nodal stage was not
statistically significantly different between N0–1 and N2-3. This
loss of stratification by PET nodal stage may reflect better staging
and, therefore, more accurate treatment of nodal sites, although
this is impossible to prove. Alternatively, it may just be because of
the small numbers and short follow-up with few events. Improved
5-year PFS for FDG-PET-staged N2–3 disease compared with CIm-
staged N2–3 disease could be consistent with more accurate nodal
staging and appropriate radiotherapy delivery.
This study does not provide information on the independent
role of PET compared with conventional staging, because the PET
results were interpreted in conjunction with other clinical
information. However, it does assess the incremental diagnostic
information provided by PET and its effect on patient management
in routine clinical practice. Accordingly, the study design reflects
the situation in which PET might be clinically applied based on
selection of patients with locally advanced disease and an
intermediate to high likelihood of occult nodal or metastatic
disease. Although PET is a valuable tool, it is expensive and, in
most centres, remains a limited resource. Therefore, the potential
effect must be balanced with the financial cost. This was not a
formal health economics study and hence the specific economic
costs have not been addressed. However, the ability to refine and
individualise treatment through more accurate pre-treatment
staging has the potential to improve outcome and reduce
recurrence, which would result in economic savings.
Stratification of patients according to local tumour stage, with
PET used in patients with tumours that are at least T2 or when
regional nodal spread is suspected on structural imaging, may
yield an acceptable level of stage and management changes to
justify the inclusion of PET on a financial basis rather than purely
a clinical one. These questions should be addressed by further
study.
In conclusion, this study is the largest published series to date
on the use of PET with SCC of the anus and showed a change in
nodal stage and subsequent radiation fields with the addition of
PET to conventional staging in a significant proportion of patients.
The effect of PET is greater in primary tumours of size 42cmas
the risk of nodal involvement is low for smaller lesions. Longer
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Figure 5 Kaplan–Meier curves of progression-free survival by N stage
by CIm (P¼0.016, log-rank test).
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sfollow-up and larger patient numbers will be needed to evaluate
the role of PET in assessing anal cancer prognosis. With treatment
strategies in anal cancer moving towards lower radiation doses and
image-guided radiotherapy treatment planning, the addition of
PET should be considered in any staging algorithm for all but the
smallest anal tumours.
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